Home > Press > Arrowhead Subsidiary Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease
Nanotechnology Holds Promise as Next Frontier in Vascular Intervention
Arrowhead Subsidiary Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease
PASADENA, CA and CHARLESTON, WV | Posted on August 3rd, 2007
Arrowhead Research Corporation (NASDAQ:ARWR) and Paragon Intellectual Properties, LCC announced today that Arrowhead's majority-owned subsidiary, Unidym Inc., has signed an exclusive license agreement with Paragon's majority-owned subsidiary, Nanotech Catheter Solutions, LLC (NCS). NCS will use Unidym's carbon nanotube technology in the development of medical devices for the treatment of cardiovascular disease. Under the terms of the agreement, Unidym will receive a 20 percent equity stake in NCS, and the parties will negotiate a supply agreement or royalty.
"We are pleased that our agreement with NCS could lead to improvements in technology to treat the millions of people around the world with cardiovascular disease," stated Art Swift, Unidym's CEO. "This agreement marks the launch of Unidym's licensing program. Our goal is to license our intellectual property and/or supply nanotubes to third parties commercializing products incorporating carbon nanotubes outside of our focus of electronics. We intend to replicate this model in other areas such as nanotube-based therapeutics, diagnostics, field emission displays, nonvolatile memory, and composite materials."
"We are thrilled about the opportunity to play a leading role in this exciting area of advanced technology," said Mark C. Bates, M.D., a leading interventional cardiologist and founder of the CAMC Vascular Center of Excellence in Charleston, West Virginia, and CEO of Paragon Intellectual Properties (the parent of NCS) and NCS. "We firmly believe that the application of nanotechnology to interventional devices such as catheters and stents could change the rules under which device designers operate, allowing them to implement improvements not previously deemed possible. This agreement with Unidym gives NCS critical intellectual property in this promising field."
About Arrowhead Research Corporation
Arrowhead Research Corporation ( http://www.arrowheadresearch.com ) is a publicly traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority-owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics, and compound semiconductor materials.
About Unidym, Inc.
Unidym ( http://www.unidym.com ) is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.
Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym’s licensing program, technical expertise, and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.
About Paragon Intellectual Properties
Paragon Intellectual Properties, LLC was founded in 2004 by Mark C. Bates, M.D., to develop innovative breakthrough solutions to complex medical problems. Headquartered in Charleston, West Virginia, with research and development in Carlsbad, California, Paragon has assembled a team of like-minded clinicians, scientists, engineers, and business leaders. Paragon’s seven subsidiaries (Apollo Therapeutics, LLC; Biflex Hybrid Stent Systems, LLC; Global Stem Cell Solutions, LLC; Nanotech Catheter Solutions, LLC; Renal Protection Solutions, LLC; Spinal Cord Injury Solutions, LLC; and Temporary Intravascular Drug Delivery Systems, LLC) hold fifty-nine issued and pending international or domestic patents. For more information about the company, please visit http://www.paragon-ip.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies; the future success of our scientific studies; our ability to successfully develop products; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory, and competitive developments; and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Arthur L. Swift, CEO, 650-462-1935
Paragon Intellectual Properties
Dan Heilbrunn, Vice President of Marketing, 604-662-3589
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Chromium-Centered Cycloparaphenylene Rings as New Tools for Making Functionalized Nanocarbons February 24th, 2015
Building tailor-made DNA nanotubes step by step: New, block-by-block assembly method could pave way for applications in opto-electronics, drug delivery February 23rd, 2015
Half spheres for molecular circuits: Corannulene shows promising electronic properties February 17th, 2015
SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Master’s Program February 13th, 2015
Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015
Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015
Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015
Optical nanoantennas set the stage for a NEMS lab-on-a-chip revolution February 24th, 2015
Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015
First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015
Leti to Offer Updates on Silicon Photonics Successes at OFC in LA February 27th, 2015
Moving molecule writes letters: Caging of molecules allows investigation of equilibrium thermodynamics February 27th, 2015
New Paper-like Material Could Boost Electric Vehicle Batteries: Researchers create silicon nanofibers 100 times thinner than human hair for potential applications in batteries for electric cars and personal electronics February 20th, 2015
Nanotech Discoveries Move from Lab to Marketplace with Lintec Deal: Licensing Partnership Brings Together University Technology, New Richardson-Based Facility Directed by Alumni February 9th, 2015
Graphenea granted patent on graphene transfer February 9th, 2015
Toronto-based Environmental Technology Pioneer Green Earth Nano Science Expands in EU February 6th, 2015